

Isolation of a high-avidity TCR directed against a treatment-induced epitope



PRINCIPAL INVESTIGATORS/COLLABORATORS

Yuen Lam Dora Ng

Antonia Busse

Jan Krönke

Charité

ATMP

Oncology

SUMMARY

Solid tumors display limited targetable antigens for conventional CAR-T cell therapy, and their targeting harbors the risk of off-target toxicity, while intracellular tumor specific antigens are inaccessible. TCR-based approaches close this gap by also recognizing intracellular antigens that are often critical drivers of oncogenesis.

Beyond known neoantigens, lineage specific antigens, and cancer testis antigens already in use, there is a gap to be filled in this space.

The team identified a novel treatment-induced cancer testis antigen and wants to characterize and set the basis for the development of a TCR-T cell strategy for its targeting.

PROJECT GOALS

- Target validation
- TCR isolation and characterization
- IP generation

LONG-TERM GOALS

- Out-licensing of IP to pharmaceutical company or spin-off formation
- Independent development and marketing of concept possibly via „Hospital Exemption“